

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Meltzer et al.

Application No.: 09/125,635

Filed: August 21, 1998

For: AIB1, A Novel Steroid Receptor Coactivator

Examiner: N. Basi

Date: May 24, 2000

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Art Unit: 1646

**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on May 24, 2000 as First Class Mail in an envelope addressed to: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

*William D. Noonan*  
William D. Noonan, M.D.  
Attorney for Applicant

B/9  
127  
6/21/00

**REPLY TO RESTRICTION REQUIREMENT (PAPER NO. 5)**

This amendment is submitted in response to the Office Action dated March 30, 2000. A one-month period for reply was set, making a response due on or before April 30, 2000. Applicant requests a one-month extension of the shortened statutory period for reply, and payment of the extension fee is enclosed with this reply.

Please amend the application as follows:

**In the claims:**

Please cancel claims 1-~~11~~ and ~~46~~, and amend the remaining claims as follows. Claims that are not amended are designated "Reiterated" for the examiner's convenience.

12. (Reiterated) A substantially pure human AIB1 polypeptide.
13. (Reiterated) The polypeptide of claim 12, wherein the polypeptide comprises the amino acid sequence of SEQ. I.D. Nos. 2, 3, 4, or 8.
14. (Reiterated) A method of identifying a candidate compound which inhibits estrogen receptor (ER)-dependent transcription comprising contacting the compound with the AIB1 polypeptide of claim 12 and determining whether the compound binds to the polypeptide, wherein binding of the compound to the polypeptide indicates that the compound inhibits ER-dependent transcription.